Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Yuko Takahashi, Takayuki Iwamoto, Yoko Suzuki, Yukiko Kajiwara, Minami Hatono, Takahiro Tsukioki, Kengo Kawada, Mariko Kochi, Hirokuni Ikeda, Tadahiko Shien, Naruto Taira, Junji Matsuoka, Hiroyoshi Doihara, Shinichi Toyooka

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

Original languageEnglish
Pages (from-to)117-124.e4
JournalClinical Breast Cancer
Volume20
Issue number2
DOIs
Publication statusPublished - Apr 2020

Keywords

  • Gene expression
  • Hormone receptor positive
  • Residual tumor burden
  • Targeted therapy
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this